Diaceutics (LON:DXRX) Stock Price Down 1.8% – Time to Sell?

Diaceutics PLC (LON:DXRX – Get Free Report)’s share price traded down 1.8% during mid-day trading on Thursday . The stock traded as low as GBX 133 and last traded at GBX 133. 43,656 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 176,776 shares. The stock had previously closed at GBX 135.50.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group lifted their target price on Diaceutics from GBX 215 to GBX 216 and gave the company a “buy” rating in a research note on Thursday, June 4th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Diaceutics presently has a consensus rating of “Buy” and a consensus target price of GBX 215.50.

Get Diaceutics alerts:

Read Our Latest Stock Report on Diaceutics

Diaceutics Trading Up 0.6%

The stock has a market cap of £114.52 million, a price-to-earnings ratio of 1,230.21 and a beta of 0.89. The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85. The business has a 50-day moving average of GBX 149.17 and a 200-day moving average of GBX 153.41.

Diaceutics (LON:DXRX – Get Free Report) last issued its earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.The company had revenue of GBX 3,844 million for the quarter. As a group, research analysts forecast that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

Diaceutics Company Profile

(Get Free Report)

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.

Further Reading

• Five stocks we like better than Diaceutics
• Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
• Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
• The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
• Why Intuitive Surgical’s Strong Quarter Still Spooked Investors

Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.